• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Bruker Corporation

    5/30/25 4:07:43 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email
    SD 1 conflict_minerals_2024.htm SD SD

     

    f

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    Form SD

    Specialized Disclosure Report

    BRUKER CORPORATION

    (Exact name of registrant as specified in its charter)

    DELAWARE

    000-30833

    04-3110160

    (State or Other Jurisdiction of Incorporation)

    (Commission File Number)

    (IRS Employer Identification Number)

    40 Manning Road, Billerica, MA 01821

    (Address of principal executive offices) (Zip Code)

    Gerald N. Herman

    (978) 663-3660

     (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

    x Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period January 1 to December 31, 2024.

     

     

     

     

     


     

    Section 1 – Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    Pursuant to Rule 13p-1 (“Rule 13p-1”) promulgated under the Securities Exchange Act of 1934, as amended, Bruker Corporation (the “Company”) has filed this Specialized Disclosure Report (“Form SD”) for the reporting period January 1, 2024, to December 31, 2024.

    A description of the measures the Company undertook to exercise due diligence on the source and chain of custody of conflict minerals contained in its Products is provided in the Conflict Minerals Report attached hereto as Exhibit 1.01. A copy of the Company’s Conflict Minerals Policy is publicly available at www.bruker.com. References in this Form SD, including the exhibits hereto, to internet websites and certain of the Company’s internal policies and procedures are provided for convenience only. The referenced documents and information available through these websites are not incorporated by reference into this Form SD.

    Item 1.02 Exhibits

    As specified in Section 2, Item 2.01 of this Form SD, the Company is hereby filing its Conflict Minerals Report as Exhibit 1.01 to this Form SD.

    Section 2 – Exhibits

    Item 2.01 Exhibits

    The following exhibit is filed as part of this report:

    Exhibit 1.01 — Conflict Minerals Report of Bruker Corporation

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

    BRUKER CORPORATION
    (Registrant)

     Date: May 30, 2025

    By:

    /s/ GERALD N. HERMAN

    Gerald N. Herman

    Executive Vice President and Chief Financial Officer

     

     


     

    Exhibit Index

     

    Exhibit No. Description

    1.01 Conflict Minerals Report of Bruker Corporation.

     

     


    Get the next $BRKR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    9/30/2024Outperform → Peer Perform
    Wolfe Research
    8/28/2024$78.00Overweight
    Wells Fargo
    6/3/2024$85.00Buy
    Jefferies
    More analyst ratings